Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein I in the paclitaxel-resistant phenotype

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3445-3453

  Duan, Zhenfeng ^a   Feller, Aynn J ^a   Penson, Richard T ^a   Chabner, Bruce A ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; DOXORUBICIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; VERAPAMIL; VINCRISTINE;

ARTICLE; CROSS RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CHEMOKINE CCL2; DNA, COMPLEMENTARY; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; OVARIAN NEOPLASMS; PACLITAXEL; PHENOTYPE; TUMOR CELLS, CULTURED; VERAPAMIL; VINCRISTINE;

EID: 0032711015     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
2. Brockstein, B., Haraf, D. J., Stenson, K., Fasammade, A., Stupp, R., Glisson, B., Lippman, S. M., Ratain, M. J., Sulzen, L., Klepsch, A., Weichselbaum, R. R., and Vokes, E. E. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J. Clin. Oncol., 16: 735-744, 1998.
3. McGuire, W. P., Blessing, J. A., Moore, D., Lentz, S. S., and Photopulos, G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J. Clin. Oncol., 14: 792-795, 1996.
4. Johnson, D. H., Paul, D. M., Hande, K. R., Shyr, Y., Blanke, C., Murphy, B., Lewis, M., and DeVore, R. F. Paclitaxel plus carboplatin in advanced non-small-cell-lung-cancer: a Phase II trial. J. Clin. Oncol., 14: 2054-2060, 1996.
5. Dunontet, C., Duran, G. E., Steger, K. A., Beketic-Oreskovic. L., and Sikic, B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res., 56: 1091-1097, 1996.
6. Lehnert, M., Emerson, S., Dalton, W. S., Giuli, R., and Salmon, S. E. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. J. Natl. Cancer Inst. Monogr., 15: 63-67, 1993.
7. Kavallaris, M., Kuo, D. Y. S., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., and Horwitz, S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invst., 100: 1282-1293, 1997.
8. Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Butters, J. T., Fojo, T., and Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272: 17118-17125, 1997.
9. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
10. Li, Y., and Benezera, R. Identification of a human mitotic checkpoint gene: hsMAD2. Science (Washington DC), 274: 246-248, 1996.
11. Heller, R. A., Schena, M., Chai, A., Shalon, D., Bedilion, T., Gilmor, J., Wooley, D. E., and Davisir, W., Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl. Acad. Sci. USA, 94: 2150-2155, 1997.
12. Zhao, N., Hashida, H., Takahashi, N., Misumi, Y., and Sakaki, Y. High-density cDNA filter analysis: a novel approach for large scale quantitation analysis of gene expression. Gene, 166: 207-213, 1995.
13. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P. O., and Davis, R. W. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl. Acad. Sci. USA, 93: 10614-10619, 1996.
14. Abbaszadegan, M. R., Foley, N. E., Gleason-Guzman, M. C., and Dalton, W. S. Resistance to the chemosensitizer verapamil in a multi-drug resistant (MDR) human multiple myeloma cell line. Int. J. Cancer, 66: 506-514, 1996.
15. Carmichael, J., Degraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
16. Yang, T. T., and Kain, S. R. A fast hybridization solution for the detection of immobilized nucleic acid. Biotechniques, 18: 498-503, 1995.
17. Liang, P., and Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (Washington DC), 257: 967-971, 1992.
18. Debouck, C. Differential display or differential dismay? Curr. Opin. Biotechnol., 6: 597-599, 1995.
19. Ledakis, P., Tanimura, H., and Fojo, T. Limitations of differential display. Biochem. Biophys. Res. Commun., 251: 653-656, 1998.
20. Langton-Webster, B. C., Xuan, J. A., Brink, J. R., and Salomon D. S. Development of resistance to cisplatin is associated with decreased expression of the gp185c-crbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ., 5: 1367-1372, 1994.
21. Volm, M., Koomagi, R., and Mttern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res., 16: 213-217, 1996.
22. Huang, T. S., Shu, C. H., Shih, Y. L., Huang, H. C., Su, Y. C., Chao, Y., Yang, W. K., and Whang-Peng, J. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett., 110: 77-85, 1996.
23. Ahn, S. H., Sawada, H., Ro, J. Y., and Nicolson, G. L. Differentail expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissue. Clin. & Exp. Metastasis, 15: 151-156, 1997.
24. Shau, H., Butterfield, L. H., Chiu, R., and Kim, A. Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. Immunogenetics, 40: 129-134, 1994.
25. Kearsey, J. M., Coates, P. J., Prescott, A. R., Warbrick, E., and Hall, P. A. Gadd45 is a nuclear cell cycle regulated protein which interacts with p21(Cip1). Oncogene, 11: 1675-1683, 1995.
26. Philips, A., Teyssier, C., Galtier F., Rivier-Covas C., Rey, J. M., Rochefort, H., and Chalbos D. FRA-1 expression level modulates regulation of activator protein-1 by estradiol in breast cancer cells. Mol. Endicronol., 12: 973-985, 1998.
27. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1-78, 1993.
28. Taga, T., and Kishimoto, T. Role of a two-chain IL-6 receptor system in immune and hematopoeitic cell regulation. Crit. Rev. Immunol., 11: 265-280, 1992.
29. Ziltener, H. J., Maines-Bandira, S., Schrader, J. W., and Auersperg, N. Secretion of bioactive IL-1, IL-6 and colony stimulating factors by human ovarian surface epithelium. Biol. Reprod., 49: 635-641, 1993.
30. Kawano, M., Hirano, T., Matsuda, T., Taga, H., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, I., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
31. Miki, S., Iwano, M., Miki, Y., Yamanoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6a (Il-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett., 250: 607-610, 1989.
32. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol. Oncol., 50: 15-19, 1993.
33. Abe, M., Quchi, N., Harada, Y., Mori, S., Rishiki, H., and Kumagai, K. Elevated serum levels of interleukin-6 in breast cancer patients with visceral metastases. Nippon Geka Gakkai Zasshi., 93: 107,1992.
34. Tempfer, C., Zeisler, H., Sliutz, G., Haeusler, G., Hanzal, E., and Kainz, C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol., 66: 27-30, 1997.
35. Thiounn, N., Pages, F., Flam, T., Tartour, E., Mosseri, V., Zerbib, M., Beuzeboc, P., Deneux, L., Fridman, W. H., and Debre, B. Il-6 is survival prognostic in renal cell carcinoma. Immunol. Lett., 58: 121-124, 1997.
36. Tartour, E., Pannetier, C., Mathiot, C., Teillaud, J. L., Sautes, C., Kourilsky, P., and Fridman, W. H. Prognostic value of cytokine and Fc γ receptor assays in oncology. Immunol. Lett., 44: 145-148, 1995.
37. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, A. M. Wild type p53 induced apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
38. Borsellino, N., Belldegrun, A., and Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res., 55: 4633-4639, 1995.
39. Tang, C., Willingham, M. C., Reed, J. C., Miyashita, T., Ray, S., Ponnathpur, V., Huang, Y., Mahoney, M. E., Bullock, G., and Bhalla, K. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia, 8: 1960-1969, 1994.
40. Tai, Y., Lee, S., Niloff, E., Weisman, C., Strobel, T., and Cannistra S. A. Bax protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol., 16: 2583-2590, 1998.
41. Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., and Fidler, L. J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res., 54: 3242-3247, 1994.
42. Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., Dipietro, L. A., Elner, V. M., Elner, S. G., and Strieter, R. M. Interleukin-8 as macrophage-derived mediator of angiogenesis. Science (Washington DC), 258: 1798-1801, 1992.
43. Radke, J., Schmidt, D., Bohme, M., Schmidt, U., Weise, W., and Morenz J. Cytokine levels in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheikd., 56: 83-87, 1996.
44. Merogi, A. J., Marrogi, A. J., Ramesh, R., Robinson, W., Fermin, C. D., and Freeman, S. M. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytesin ovarian carcinomas. Hum. Pathol., 28: 321-331, 1997.
45. Yoneda, J., Kuniyasu, H., Crispins, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J., Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst., 90: 447-454, 1998.
46. Lee, L. F., Schuerer-Maly, C. C., Lofquist, A. K., van Haaften-Day, C., Ting, J. P., White, C. M., Martin, B. K., and Haskill, J. S. Taxol-dependent transcriptional activation of Il-8 expression in a subset of human ovarian cancer. Cancer Res., 56: 1303-1308, 1996.
47. Baggiolini, M., Dewald, B., and Moser, B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol., 55: 97-179, 1993.
48. Schall, T. J.,and Bacon, K. B. Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol., 6: 865, 1994.
49. Negus, R. P. M., Stamp, G. W. H., Hadley, J., and Balkwill, F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Path., 150: 1723-1734, 1997.
50. Negus, R. P. M., Stamp, G. W. H., Relf, M. G., Burke, F., Malik, S. T. A., Bernasconi, S., Allavena, P., Sozzani, S., Mantovani, A., and Balkwill, F. R. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest., 95: 2391-2396,1995.